Bio-Rad Laboratories, Inc.

Valuation Analysis

About the Company

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharm

Bio-Rad Laboratories, Inc. Stock at a Glance

Bio-Rad Laboratories, Inc. (BIO) is currently trading at $285.94 with a market capitalization of $7.7B. The trailing P/E ratio stands at 47.66x, with a forward P/E of 29.41x. The 52-week range spans from $222.80 to $343.12; the current price is 16.7% below the yearly high. Year-over-year revenue growth stands at +1.1%. The net profit margin stands at 6.52%.

💰 Dividend

Bio-Rad Laboratories, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

5 analysts rate Bio-Rad Laboratories, Inc. (BIO) on consensus: None. The average price target is $297.00, implying +3.87% from the current price. Analyst price targets range from $275.00 to $320.00.

Bio-Rad Laboratories, Inc.: The Investment Case in Detail

Bio-Rad Laboratories, Inc. (BIO) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 1.1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

At a PEG of 4.01, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

What to Watch Next

• The forward P/E of 29.41x is meaningfully below the trailing 47.66x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy Bio-Rad Laboratories, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.